David Lemus - 02 Jan 2025 Form 3 Insider Report for Silence Therapeutics plc (SLN)

Role: Director
Signature: /s/ Rhonda Hellums, Attorney-in-Fact
Issuer symbol: SLN
Transactions as of: 02 Jan 2025
Net transactions value: $0
Form type: 3
Filing time: 02 Jan 2025, 16:29:40 UTC
Previous filing: 18 Oct 2024
Next filing: 06 Jan 2026
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	SLN	Ordinary Shares						7,527	02 Jan 2025	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	SLN	Share Option (Right to Buy)							02 Jan 2025	Ordinary Shares	48,000	$7.87	Direct	F1
holding	SLN	Share Option (Right to Buy)							02 Jan 2025	Ordinary Shares	48,000	$5.13	Direct	F2
holding	SLN	Share Option (Right to Buy)							02 Jan 2025	Ordinary Shares	48,000	$5.90	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option vested or shall vest in equal monthly installments over a three-year period measured from one month following January 6, 2022, subject to the Reporting Person's continuous service as of the applicable vesting date.
F2	This option vested or shall vest in equal monthly installments over a three-year period measured from one month following September 14, 2023, subject to the Reporting Person's continuous service as of the applicable vesting date.
F3	This option vested or shall vest in equal monthly installments over a three-year period measured from one month following January 4, 2024, subject to the Reporting Person's continuous service as of the applicable vesting date.